Safety and Efficacy of BAY94-9027 in Previously Treated Male Children With Haemophilia A

Study drug dosing was adjusted to the clinical needs of each subject in the range of 25-60 IU/kg/administration, intravenous infusion, at least 50 EDs and a minimum of at least 6 months

Twice per week prophylaxis: 25-60 IU/kg, intravenous infusion, for 12 weeks

Study drug dosing was adjusted to the clinical needs of each subject in the range of 25-60 IU/kg/administration, intravenous infusion, at least 50 additional EDs to achieve at least 100 cumulative EDs, or until marketing authorization of the drug